In 2019, the FDA approved pexidartinib (Turalio), a small-molecule immunomodulator that targets the cytokine “colony stimulating factor-1(CSF-1)” receptor pathway, to treat symptomatic tenosynovial giant cell tumor [109]. Here, CSF1 is linked to tenosynovial giant cell tumor.